Merck: Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care

Not intended for US-, Canada- and UK-based media First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative

Related Keywords

United States ,Canada ,Le Tourneau ,Amanda Hollinger ,Sun Xs Tao ,Jean Bourhis ,Head Of Development Unit Oncology ,Merck Press ,Drug Administration ,Department Head Of Radio ,European Society Of Medical Oncology Congress ,Neck Cancer Alliance ,Serono ,University Hospital Of Lausanne ,United Kingdom Based ,European Society ,Medical Oncology Congress ,Department Head ,University Hospital ,Executive Director ,Neck Cancer ,Victoria Zazulina ,Development Unit Oncology ,Breakthrough Therapy Designation ,Merck Press Releases ,Sunx S ,Merck ,Xevinapant ,Five ,Ear ,Data ,Show ,Survival ,Gate ,Early ,Oubled ,Patients ,Nresected ,Cchn ,When ,Dded ,Standard ,Mare ,